ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ATRA" rel="nofollow">ATRA</a>) investment, contact <a href="https://www.globenewswire.com/Tracker?data=fKokx0ewf4XTApFzFY39tmt-bcNXjj5XYgjrpq0OiN2GHPMJ7EsXmUOKmWcYFxDkLfMu4Yb1rswd_uWMlYFs6spx4GdUh2ikdNUt5gQ4jYF_2euyR1GzOQ-YaVi6MggJ" rel="nofollow" target="_blank" rel="nofollow">Lauren Molinaro</a> of Kirby McInerney LLP by email at <a href="https://www.globenewswire.com/Tracker?data=4CsUCTKoGSt2Naq4Pe_S_shsGjT-1mOGfIz2RxCLctjyAm5ZVsViXJxTPeYe9-u7Gr0bM8_Vr7MZ24FQuGIqZCQ59NvJfNO68xke1GcIKIHtowdjQ-Vr_mXaZW1DRon2" rel="nofollow" target="_blank" rel="nofollow">[email protected]</a>, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.</p> <p align="justify">Investors have until May 22, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.</p> <p align="center">[<a href="https://www.globenewswire.com/Tracker?data=f6upyCiFsvULmLuuaxCXfz1KrMtyWHUoVV6wC6hW15VcqC0G7xefp_ZLF1QvsHtM4P0Y5Tjk58pQ8Ue70wyFH3VA47gGxzzYxINxRe3hbppkViuWkOwKPoD39rQKRoeTpFxF_hLrpeCz48RVKxlak_ND_C1LjuXG8IR7CcrdrByy448V1oM3M9jblsHjX5Qf" rel="nofollow" target="_blank" rel="nofollow">CONTACT THE FIRM IF YOU SUFFERED A LOSS</a>]</p> <p align="justify"><strong>What Is The Lawsuit About?</strong></p> <p align="justify">The lawsuit has been filed on behalf of investors who purchased securities during the period of May 20, 2024 through January 9, 2026, inclusive ("the Class Period"). The lawsuit alleges that (i) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel's regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk ...</p><p><a href=https://www.benzinga.com/pressreleases/26/04/g51694474/atra-investor-reminder-atara-biotherapeutics-inc-investors-have-until-may-22-2026-to-seek-lead-pla?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel alt=ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role>Full story available on Benzinga.com</a></p>